The outcome of a positive Rituximab trial for ME/CFS – possibly, finally, an FDA approved drug, relief for many, acceptance for this disease, increased research fund – would have been spectacular but Dr. Mella reported this week in Norway that the trial unfortunately failed.
We won’t exactly how it failed until next year but the failure almost certainly means that Rituximab will not be the next FDA approved drug for ME/CFS.
That doesn’t mean Rituximab’s role in ME/CFS is necessarily over, however, and the Rituximab saga has brought much to the ME/CFS field. Read more about it in a Simmaron Research Foundation sponsored blog:
Over a million users visited Health Rising’s 1,000 blogs, posts and pages last year. HR was able to achieve this with a small budget (@ $40,000/year) which supported one full-time and one part-time person, several volunteers (and one busy website).
The difference Health Rising could make, however, could be so much greater. Please support Health Rising with your recurring (as low as $5/month) or one-time donations, and help it spread the word on these disease’s needs, their findings and treatments. Find out more here..